Biogen

Biogen

Yahoo Finance • yesterday

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now

In a significant development for Alzheimer's diagnostics, the U.S. Food and Drug Administration (FDA) has recently granted clearance to the Elecsys pTau217 blood test, developed jointly by healthcare giants Eli Lilly LLY and Roche RHHBY. T... Full story

Yahoo Finance • 2 days ago

Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ...

This article first appeared on GuruFocus. Total Revenue: $928 million in Q2 fiscal 2027. Non-GAAP Operating Income: $416 million for the quarter. CRM Performance: Best CRM quarter ever recorded. AI Progress: Accelerating momentum in AI, p... Full story

Yahoo Finance • 3 days ago

Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says

Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 days ago

3 Reasons to Sell BIIB and 1 Stock to Buy Instead

3 Reasons to Sell BIIB and 1 Stock to Buy Instead Biogen has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 per share while the index has gai... Full story

Yahoo Finance • 3 days ago

Veeva Vault CRM Selected by Biogen

Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally.Veeva Vault... Full story

Yahoo Finance • 7 days ago

Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected laun... Full story

Yahoo Finance • 7 days ago

What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders

In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined... Full story

Yahoo Finance • 9 days ago

Real Parkinson’s Disease Hope from Jupiter Neurosciences

By Mike Sheikh Parkinson's Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate.   The market isn't recognizing the story yet... Full story

Yahoo Finance • 10 days ago

Trump expected to nominate White House aide Heidi Overton as FDA commissioner

[FDA Headquarters] President Donald Trump is expected to tap Heidi Overton, a top aide at the White House’s Domestic Policy Council, to serve as the next commissioner of the Food and Drug Administration, according to multiple media report... Full story

Yahoo Finance • 14 days ago

Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s

[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults... Full story

Yahoo Finance • 17 days ago

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life science... Full story

Yahoo Finance • 22 days ago

Biogen Completes Acquisition of RayThera Inc.

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecul... Full story

Yahoo Finance • 23 days ago

Biogen Stock: How To Find & Own America's Greatest Opportunities

Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold. Continue Reading... Full story

Yahoo Finance • 27 days ago

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to the S&P 500 healthcare sector at a low cost, whereas the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets a concentrated niche of biotechnol... Full story

Yahoo Finance • 29 days ago

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) offers a focused, high-momentum approach to the biotechnology sector, while the Vanguard Health Care ETF (NYSEMKT:VHT) provides broad, low-cost exposure across the entire healthcare land... Full story

Yahoo Finance • 30 days ago

Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acqu... Full story

Yahoo Finance • 30 days ago

Why This Drugmaker’s Earnings Guidance Cut Doesn’t Tell the Full Story

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter. Continue Reading... Full story

Yahoo Finance • 30 days ago

Stocks making the biggest moves premarket: Biogen, Vertiv, GE HealthCare, Generac & more

Check out the companies making the biggest moves premarket: Biogen — Shares were up 0.7% after the biotechnology company beat Wall Street consensus on revenue. The company also raised its full-year adjusted EPS guidance. Vertiv — The AI in... Full story

Yahoo Finance • 30 days ago

Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales

Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts' estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Al... Full story

Yahoo Finance • 30 days ago

Biogen Raises Revenue Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter. Continue Reading... Full story